Literature DB >> 24188705

Rectal pre-exposure prophylaxis (PrEP).

Lisa C Rohan1, Haitao Yang, Lin Wang.   

Abstract

Rectal pre-exposure prophylaxis (PrEP) will be a critical component of HIV prevention products due to the prevalence of unprotected receptive anal intercourse among men who have sex with men and heterosexual couples. Given the biological considerations of this compartment and the complexity of HIV infection, design of a successful rectal microbicide product faces a number of challenges. Important information is being compiled to begin to address deficits in knowledge toward design of rectal PrEP products for men and women. Aspects of formulation development and preclinical and clinical evaluation of rectal products studied to date are summarized in this review. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIV prevention; Microbicides; Rectal pre-exposure prophylaxis

Mesh:

Substances:

Year:  2013        PMID: 24188705      PMCID: PMC3896093          DOI: 10.1016/j.antiviral.2013.09.023

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  67 in total

1.  Reformulated tenofovir gel for use as a dual compartment microbicide.

Authors:  Charlene S Dezzutti; Lisa C Rohan; Lin Wang; Kevin Uranker; Cory Shetler; Marilyn Cost; J D Lynam; David Friend
Journal:  J Antimicrob Chemother       Date:  2012-05-11       Impact factor: 5.790

2.  Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Authors:  Sarah Harman; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

3.  Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

Authors:  Salim S Abdool Karim; Angela D M Kashuba; Lise Werner; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

4.  Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.

Authors:  Anthony S Ham; Shweta R Ugaonkar; Lianjun Shi; Karen Watson Buckheit; Howard Lakougna; Umadevi Nagaraja; Garry Gwozdz; Laurie Goldman; Patrick F Kiser; Robert W Buckheit
Journal:  J Pharm Sci       Date:  2012-01-06       Impact factor: 3.534

Review 5.  Rectal microbicide development.

Authors:  Ian McGowan
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

6.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

7.  Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.

Authors:  Heather A Pines; Pamina M Gorbach; Robert E Weiss; Kristen Hess; Ryan Murphy; Terry Saunders; Joelle Brown; Peter A Anton; Ross D Cranston
Journal:  AIDS Behav       Date:  2013-03

8.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.

Authors:  Morgan L Chateau; Paul W Denton; Michael D Swanson; Ian McGowan; J Victor Garcia
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  2 in total

Review 1.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.

Authors:  Lauren Girard; Kenzie Birse; Johanna B Holm; Pawel Gajer; Mike S Humphrys; David Garber; Patricia Guenthner; Laura Noël-Romas; Max Abou; Stuart McCorrister; Garrett Westmacott; Lin Wang; Lisa C Rohan; Nobuyuki Matoba; Janet McNicholl; Kenneth E Palmer; Jacques Ravel; Adam D Burgener
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.